Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

Alex Bazeos, Jamshid Khorashad, François-Xavier Mahon, Lina L Eliasson, Dragana Milojkovic, Marco Bua, Jane Apperley, Richard Szydlo, Kasia Kozlowski, Christos Paliompeis, Ritti Desai, Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katy Rezvani, John Goldman, David Marin

Blood (2009) 114 (22): 3290.

https://doi.org/10.1182/blood.V114.22.3290.3290

Published: 2009

Journal Articles

Front-Line Imatinib Mesylate (IM) in Patients with Newly Diagnosed Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML), a Study From the FILMC Group (France Intergroupe Leucemie Myeloide Chronique).

Delphine Rea, MD, PhD, Gabriel Etienne, MD, Franck Emmanuel Nicolini, MD, PhD, Pascale Cony-Makhoul, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD, Francoise Huguet, MD, Michel Tulliez, MD, Martine Gardembas, MD, Krimo Bouabdallah, MD, Philippe Rousselot, MD, PhD, Jean-Michel Cayuela, PhD, Herve Dombret, MD, PhD, François-Xavier Mahon, MD, PhD

Blood (2009) 114 (22): 3288.

https://doi.org/10.1182/blood.V114.22.3288.3288

Published: 2009

Journal Articles

Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.

Blood (2009) 114 (22): 2199.

https://doi.org/10.1182/blood.V114.22.2199.2199

Published: 2009

Journal Articles

Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.

Michael Deininger, MD, PhD, François-Xavier Mahon, MD, Francois Guilhot, MD, Giuseppe Saglio, MD, Philipp le Coutre, MD, Arnon Nagler, MD, Anna D'Emilio, MD, Fabio Stagno, Enrica Morra, MD, Andrea Piccin, MD, Sarit E. Assouline, MD, Elisabetta Abruzzese, Valeria Santini, MD, Fabrizio Pane, MD, Pilar Giraldo, MD, Laura Antolini, PhD, Maria Grazia Valsecchi, PhD, Carlo Gambacorti-Passerini, MD

Blood (2009) 114 (22): 1108.

https://doi.org/10.1182/blood.V114.22.1108.1108

Published: 2009

Journal Articles

Imatinib Trough Plasma Concentration and Its Correlation with Clinical Response in Chronic Phase and Accelerated Phase of CML

Kajetana Foryciarz, Mathieu Molimard, François-Xavier Mahon, Izabela Florek, Tomasz Sacha, Marcin Sobocinski, Aleksander B. Skotnicki

Blood (2008) 112 (11): 4269.

https://doi.org/10.1182/blood.V112.11.4269.4269

Published: 2008

Journal Articles

Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients.

Carlo Gambacorti-Passerini, Dong-Wook Kim, François-Xavier Mahon, Giuseppe Saglio, Fabrizio Pane, François Guilhot, Michael W.N. Deininger, Arnon Nagler, Alessandro Rambaldi, Enrica Morra, Laura Antolini, IL-Young Kweon, Josy Reiffers, Lucia Tornaghi, Maria Grazia Valsecchi

Blood (2008) 112 (11): 1099.

https://doi.org/10.1182/blood.V112.11.1099.1099

Published: 2008

Journal Articles

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

Blood (2008) 112 (11): 183.

https://doi.org/10.1182/blood.V112.11.183.183

Published: 2008

Journal Articles

Defensine Alpha1 as a New Marker of Imatinib Resistance in Chronic Myelogenous Leukemia

Gabriel Etienne, Maryse Dupouy, Claudine Chollet, Jean-Max Pasquet, Eric Lippert, Josy Reiffers, François- Xavier Mahon, Beatrice Turcq

Blood (2008) 112 (11): 3180.

https://doi.org/10.1182/blood.V112.11.3180.3180

Published: 2008

Journal Articles

High Efficacy and Particular Safety Profile of Imatinib Mesylate (Glivec®) in Elderly Patients with CML in Chronic Phase: Results of the AFR04 Prospective Study.

Philippe Rousselot, Franck Nicolini, François Xavier Mahon, Delphine Réa, Jérome Jaubert, Christian Berthou, Josy Reiffers, Joelle Guilhot, François Guilhot

Blood (2007) 110 (11): 1039.

https://doi.org/10.1182/blood.V110.11.1039.1039

Published: 2007

Journal Articles

Pharmacological Blockade of NF-kB Targets Both Imatinib-Sensitive or -Resistant Chronic Myeloid Leukemia Cells for Cell Death.

Véronique Imbert, PhD, Nadia Lounnas, Catherine Frelin, PhD, Nadège Gonthier, Emmanuel Griessinger, Nicolas Sirvent, MD, Michael Hummelberger, MD, Jil-Patrice Cassuto, MD, François-Xavier Mahon, MD, Jean-François Michiels, MD, Philippe Rousselot, MD, Michel Dreano, PhD, Jean-François Peyron, PhD

Blood (2006) 108 (11): 4793.

https://doi.org/10.1182/blood.V108.11.4793.4793

Published: 2006

Journal Articles

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Franck E. Nicolini, MD, PhD, Emmanuel Bachy, MD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Dominique Bories, MD, PhD, Michel Tulliez, MD, Nathalie Sorel, MD, Francois Guilhot, MD, Laurence Legros, MD, François-Xavier Mahon, MD, PhD, Frédéric Maloisel, MD, Jean-Jacques Kiladjian, MD, PhD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2006) 108 (11): 2190.

https://doi.org/10.1182/blood.V108.11.2190.2190

Published: 2006

Journal Articles

Correlations between BCR-ABL Ratio and Cytogenetic Response at Months 12 of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

Claude Preudhomme, MD, PhD, Catherine Roche-Lestienne, MD/PHD, Antoine Crinquette, MD, Christophe Roumier, MD/PHD, Virginie Eclache, MD, Joëlle Guilhot, MD, Francois Guilhot, MD/PHD, François-Xavier Mahon, MD/PHD

Blood (2006) 108 (11): 2150.

https://doi.org/10.1182/blood.V108.11.2150.2150

Published: 2006

Journal Articles

First Overall Molecular Response of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

Catherine Roche-Lestienne, MD, PhD, François-Xavier Mahon, MD/PHD, Antoine Crinquette, MD, Joëlle Guilhot, PhD, Francois Guilhot, MD/PHD, Claude Preudhomme, MD/PHD

Blood (2006) 108 (11): 2151.

https://doi.org/10.1182/blood.V108.11.2151.2151

Published: 2006

Journal Articles

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Philippe Rousselot, Francoise Huguet, Delphine Rea, Laurence Legros, Jean Michel Cayuela, Odile Maarek, Odile Blanchet, Gerald Marit, Eliane Gluckman, Josy Reiffers, Martine Gardembas, François-Xavier Mahon, The Intergroupe Français des Leucémies Myéloïdes Chronique (FIφLMC)

Blood (2006) 109 (1): 58–60.

https://doi.org/10.1182/blood-2006-03-011239

Published: 2006

Journal Articles

Heat Shock Protein 70 over Expression Is Associated to Imatinib Resistance in Chronic Myelogenous Leukemia.

Marion Pocaly, Valérie Lagarde, Gabriel Etienne, Jean-Antoine Ribeil, Marc Bonneu, Stéphane Claverol, François Moreau-Gaudry, Olivier Hermine, Béatrice Turcq, François-Xavier Mahon, Jean-Max Pasquet

Blood (2005) 106 (11): 2005.

https://doi.org/10.1182/blood.V106.11.2005.2005

Published: 2005

Journal Articles

BCR/ABL Oncogene Controls MICA Translation.

Nicolas Boissel, Delphine Rea, Vannary Tieng, Nicolas Dulphy, Manuel Brun, Jean-Michel Cayuela, Philippe Rousselot, Ryad Tamouza, Philippe Le Bouteiller, François-Xavier Mahon, Alexander Steinle, Dominique Charron, Hervé Dombret, Antoine Toubert

Blood (2005) 106 (11): 4389.

https://doi.org/10.1182/blood.V106.11.4389.4389

Published: 2005

Journal Articles

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Franck E. Nicolini, MD, PhD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Nathalie Sorel, PhD, Dominique Bories, MD, PhD, Stéphane Giraudier, MD, PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Jean-Michel Cayuela, MD, François-Xavier Mahon, MD, PhD, Pascale Cony-Makhoul, MD, Jean-Jacques Kiladjian, MD, Olivier Tournilhac, MD, François Guilhot, MD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2005) 106 (11): 3284.

https://doi.org/10.1182/blood.V106.11.3284.3284

Published: 2005

Journal Articles

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Franck E. Nicolini, MD, PhD, Nathalie Grardel, MD, Sandrine Hayette, PhD, Jean-Michel Cayuela, MD, Agnès Buzyn, MD, PhD, Eric Delabesse, MD, Christian Bastard, MD, Odile Blanchet, MD, Nathalie Sorel, PhD, Marie-Josée Mozziconacci, MD, Ali Turhan, MD, PhD, Virginie Eclache, MD, François-Xavier Mahon, MD, PhD, Nicole Dastugue, MD, Eric Legac, MD, Marie-Pierre Gaub, MD, Sélim Corm, MD, Claude Preudhomme, MD, PhD

Blood (2005) 106 (11): 3285.

https://doi.org/10.1182/blood.V106.11.3285.3285

Published: 2005

Journal Articles

Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.

Agnès Guerci, MD, Franck Nicolini, MD, Frederic Maloisel, MD, Selim Corm, MD, Laurence Legros, MD, Françoise Rigal-Huguet, MD, Philippe Rousselot, MD, Krimo Bouabdallah, MD, Martine Gardembas, MD, Anne Vekoff, MD, Jean-Jacques Kiladjian, MD, Martine Delain, MD, François-Xavier Mahon, MD, Claude Preudhomme, MD, Joelle Guilhot, BS, François Guilhot, MD

Blood (2005) 106 (11): 168.

https://doi.org/10.1182/blood.V106.11.168.168

Published: 2005

Journal Articles

Bim-EL, Is Sensitive to Proteasome Degradation and Contributes to Inducing Apoptosis after In Vitro Imatinib Mesylate Treatment of BCR-ABL Positive Cells.

Francis Belloc, PhD, Catherine Boyer, Francis Lacombe, MD, PhD, Vincent Praloran, MD, François-Xavier Mahon, MD, PhD

Blood (2004) 104 (11): 4676.

https://doi.org/10.1182/blood.V104.11.4676.4676

Published: 2004

NARROW

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

Front-Line Imatinib Mesylate (IM) in Patients with Newly Diagnosed Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML), a Study From the FILMC Group (France Intergroupe Leucemie Myeloide Chronique).

Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.

Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.

Imatinib Trough Plasma Concentration and Its Correlation with Clinical Response in Chronic Phase and Accelerated Phase of CML

Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients.

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

Defensine Alpha1 as a New Marker of Imatinib Resistance in Chronic Myelogenous Leukemia

High Efficacy and Particular Safety Profile of Imatinib Mesylate (Glivec®) in Elderly Patients with CML in Chronic Phase: Results of the AFR04 Prospective Study.

Pharmacological Blockade of NF-kB Targets Both Imatinib-Sensitive or -Resistant Chronic Myeloid Leukemia Cells for Cell Death.

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Correlations between BCR-ABL Ratio and Cytogenetic Response at Months 12 of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

First Overall Molecular Response of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Heat Shock Protein 70 over Expression Is Associated to Imatinib Resistance in Chronic Myelogenous Leukemia.

BCR/ABL Oncogene Controls MICA Translation.

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.

Bim-EL, Is Sensitive to Proteasome Degradation and Contributes to Inducing Apoptosis after In Vitro Imatinib Mesylate Treatment of BCR-ABL Positive Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only